-
Daiichi Sankyo2024-08-06 16:38:29Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe
-
Daiichi Sankyo2024-08-06 16:38:40First-in-class cholesterol-lowering treatment NILEMDO®▼ and its combination with ezetimibe, NUSTENDI®▼,
-
Daiichi Sankyo2024-03-25 09:37:57CHMP issues positive opinions for both bempedoic acid and the bempedoic acid / ezetimibe fixed-dose
-
Daiichi Sankyo2024-03-25 10:05:10Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small
-
Daiichi Sankyo2024-02-15 11:44:37Daiichi Sankyo investiert ca. eine Milliarde Euro in Deutschland: Standort Pfaffenhofen (Bayern) wird zu
-
Daiichi Sankyo2024-01-11 10:13:05Declaration of Principle Supply Chain Due Diligence Act
-
Daiichi Sankyo2024-01-03 13:44:14Esperion and Daiichi Sankyo Europe Announce $125 Million Amendment to Their Collaboration, Including
-
Daiichi Sankyo2023-11-09 08:10:56VANFLYTA® Approved in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed
-
Daiichi Sankyo2023-11-06 08:21:48Change in Leadership at Daiichi Sankyo Europe
-
Daiichi Sankyo2023-10-23 08:14:19ENHERTU® Approved in the EU as the First HER2 Directed Therapy for Patients with HER2 Mutant Advanced